OS Fund

OS Fund is an American venture capital fund that invests in early-stage science and technology companies.[1][2]

OS Fund
TypePrivate
Founded2014
FounderBryan Johnson, Jeff Klunzinger
HeadquartersChicago
ProductsVenture capital
WebsiteOSFund.co

Firm

Bryan Johnson created OS Fund in October 2014, a year after he sold Braintree, a mobile payment processing company he founded in 2007, to eBay for $800 million.[3] Together with Jeff Klunzinger, the former CFO of West Family Investments, the Fund was launched with $100 million of personal capital; Johnson and Klunzinger serve as the fund’s General Partners.[4][5]

The fund draws its name from the acronym for operating system (OS), the software that underlies the basic functions of computers and provides a foundation for other applications. OS Fund focuses on investment in technologies and platforms in genomics, synthetic biology, computationally derived therapeutics, advanced materials, and diagnostics.[6]

In September 2015, OS Fund published the methodology it uses to evaluate investments in the field of synthetic biology. Johnson said the fund publicly released the "playbook" on its website to encourage others to invest in emerging sciences.[7]

Origins

Johnson spent two years in impoverished Ecuadorian communities and, at age 21, was motivated by his experience to set a goal to build a company, retire by age 30, and then devote himself and his resources to improving the lives of others.[3][8] In line with these interests, in response to a pullback in federal support of research and development,[9] and because of a general reluctance by more traditional venture capital firms to make science-related investments that could lead to disruptive change, Johnson created OS Fund.[10]

Investments

OS Fund focuses on early-stage, computationally driven companies that utilize artificial intelligence and machine learning to develop platform technologies in the following sectors:

OS Fund notes that its earliest investments--which demonstrated a wider range of subject matters--were entirely self-funded as they proved their investment thesis and built their core team.[11]

Notable OS Fund investments include the following:

  • Ginkgo Bioworks, a Boston-based biotechnology company that uses genetic engineering to produce bacteria with industrial applications; recently valued at $4.2 billion.[12][13][14]
  • NuMat Technologies, pioneers of metal-organic frameworks that utilize high-performance computing to design material-enabled products.
  • Atomwise, a San Francisco-based developer of an AI-powered drug discovery platform.[15]
  • Arzeda, a protein and enzymatic design platform used to develop transformative products across industries
  • twoXAR, an AI-driven drug discovery platform.[16]
  • Lygos, a biological engineering platform that converts low-cost sugar to high-value chemicals.
  • Tempo, a software-driven smart factory that merges data, analytics, and automation to rapidly and precisely print complex circuit board assemblies.
  • Truvian, a benchtop blood testing diagnostic system that provides lab-accurate results in 20 minutes.
  • Catalog, a Boston company focused on harnessing DNA to store data. The company recently showed it could store 14 gigabytes of data from Wikipedia.org in DNA molecules.[17]
  • A-Alpha Bio, a drug discovery platform that simultaneously sorts through millions of protein interactions for multiple targets.
  • JUST, a San Francisco-based food technology company focused on sustainable plant-based food products, a 100% plant-based egg alternative made from mung beans.
  • Matternet, the builder and operator of drone logistics networks to transport goods on demand. In 2019, they partnered with UPS to transport medical samples across hospital systems as well as UPS and CVS Pharmacy to make at-home prescription deliveries.[18]

References
  1. "OS Fund LLC: Private Company Information". Bloomberg. Retrieved 8 June 2015.
  2. "Bryan Johnson-Founder at OS Fund". CrunchBase. Retrieved 8 June 2015.
  3. Dameron, Emerson (October 21, 2014). "Departed Braintree founder starts $100 million venture fund". Built In Chicago. Retrieved 7 June 2015.
  4. Mims, Christopher (October 20, 2014). "Humanity's Last Great Hope: Venture Capitalists". Wall Street Journal. Retrieved 7 June 2015.
  5. "About". OS Fund. Retrieved 8 June 2015.
  6. Johnson, Bryan (October 20, 2014). "Rewrite the OS, Change the World". Medium. Retrieved 7 June 2015.
  7. Knapp, Alex (September 15, 2015). "Braintree Founder Unveils Open Source Playbook For Science Investors". Forbes. Retrieved October 8, 2015.
  8. Pletz, John (June 29, 2011). "Startup Braintree gets funding from Accel Partners". Crain’s Chicago Business. Retrieved 3 May 2015.
  9. Mims, Christopher (October 20, 2014). "Humanity's Last Great Hope: Venture Capitalists". The Wall Street Journal. Retrieved 8 June 2015.
  10. "Manifesto". OS Fund. Retrieved 8 June 2015.
  11. "Working With Us". OS Fund. Retrieved 8 June 2015.
  12. Gormley, Brian (March 18, 2015). "Ginkgo Bioworks Raises $9M to 'Engineer' Food Flavors, Fragrances". The Wall Street Journal. Retrieved 8 June 2015.
  13. Buhr, Sarah. "Why The First YC-Backed Biotech Company May Just Be The Future Of Pharma". TechCrunch. Retrieved 8 June 2015.
  14. "Ginkgo Bioworks Secures $45 Million from Viking Global, OS Fund, Y Combinator and Felicis Ventures" (Press release). Boston: Business Wire. July 23, 2015. Retrieved October 8, 2015.
  15. Buhr, Sarah (June 3, 2015). "YC Alum Atomwise Raises $6 Million To Further The Advancement Of Artificial Intelligence In Drug Discovery". TechCrunch. Retrieved October 8, 2015.
  16. Klunzinger, Jeff (2018-07-24). "Moving drug discovery into the fast lane: OS Fund invests in twoXAR's AI-driven approach". Medium. Retrieved 2019-11-01.
  17. Castellanos, Sara (2020-02-05). "Where Computing Is Headed—Beyond Quantum". Wall Street Journal. ISSN 0099-9660. Retrieved 2020-05-25.
  18. Mangalindan, JP (October 20, 2014). "Crazy, insane start-ups are this tech investor's meat and potatoes". Fortune. Retrieved 8 June 2015.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.